AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34599167 — intervention group
Group type: EXPERIMENTAL
Intervention: Short educational video during four well-child visits with pediatrician
Number of subjects: 0
Study 34599167 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve home visits with feedback based on daily interactions with their child
Number of subjects: 0
Study 32583948 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with lenalidomide and dexamethasone (POLLUX)
Number of subjects: 1067
Study 32583948 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with bortezomib and dexamethasone (CASTOR)
Number of subjects: 1067
Study 32583948 — intervention group
Group type: COMPARATOR
Intervention: Active controls (lenalidomide and dexamethasone, bortezomib and dexamethasone)
Number of subjects: 1067
Study 33581737 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (CG) 100 mg
Number of subjects: 29
Study 33581737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 33154545 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of deferring gratification based on a speaker's promise
Number of subjects: 32
Study 33154545 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of instant gratification when no promise was made
Number of subjects: 32
Study 34262668 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Problem Management Plus (GroupPM+)
Number of subjects: 35
Study 34262668 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 35
Study 33049696 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart glasses group
Number of subjects: 20
Study 33049696 — intervention group
Group type: COMPARATOR
Intervention: Nonglasses group
Number of subjects: 20
Study 36214938 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable prosthesis and individualized swallowing function training
Number of subjects: 16
Study 33752174 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed diabetes mellitus-related hyperglycemia (NDDM-RH)
Number of subjects: 3026
Study 33752174 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hyperglycemia
Number of subjects: 3026
Study 33752174 — intervention group
Group type: COMPARATOR
Intervention: Previously diagnosed diabetes mellitus (PDDM)
Number of subjects: 3026
Study 32034079 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination intervention, details not specified
Number of subjects: 0
Study 32034079 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35148573 — intervention group
Group type: EXPERIMENTAL
Intervention: HS016
Number of subjects: 502
Study 35148573 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 502
Study 34100769 — intervention group
Group type: EXPERIMENTAL
Intervention: RealRisks web-based decision aid (DA)
Number of subjects: 300
Study 34100769 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials
Number of subjects: 300
Study 35617272 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended web-based rehabilitation program (6-week duration) consisting of exercise and advice material enhanced with outdoor structured physical activity.
Number of subjects: 56
Study 35617272 — intervention group
Group type: COMPARATOR
Intervention: Outdoor structured physical activity alone (control group).
Number of subjects: 56
Study 33579842 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver strain
Number of subjects: 301
Study 33579842 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver age
Number of subjects: 301
Study 33579842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment of the person with dementia
Number of subjects: 301
Study 33579842 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression of the person with dementia
Number of subjects: 301
Study 33579842 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety of the person with dementia
Number of subjects: 301
Study 36367616 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐rTMS (19 sessions over 4 weeks)
Number of subjects: 28
Study 33983794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 97/103mg twice daily
Number of subjects: 93
Study 33983794 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160mg twice daily
Number of subjects: 93
Study 33415867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread-embedding therapy
Number of subjects: 68
Study 33415867 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture therapy
Number of subjects: 68
Study 35534640 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic arterial pulsatility index (SAPi)
Number of subjects: 142
Study 35534640 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study 34261541 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg Q4W
Number of subjects: 1120
Study 34261541 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg Q8W
Number of subjects: 1120
Study 34261541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 35164841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, multi-faceted intervention based on the guideline (interactive educational symposium plus academic detailing)
Number of subjects: 1358
Study 35164841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, multi-faceted intervention based on the guideline
Number of subjects: 1358
Study 35164841 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination of the guideline (control group)
Number of subjects: 1358
Study 33174080 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefits presented before risks (BR)
Number of subjects: 156
Study 33174080 — intervention group
Group type: EXPERIMENTAL
Intervention: Risks presented before benefits (RB)
Number of subjects: 156
Study 33174080 — intervention group
Group type: EXPERIMENTAL
Intervention: All attributes randomised (RN)
Number of subjects: 156
Study 33174080 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterministic attribute grouping
Number of subjects: 156
Study 33174080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominance and stability tests
Number of subjects: 156
Study 36013132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐based toothpaste plus mouthwash (Trial group)
Number of subjects: 0
Study 36013132 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste alone (Control Group)
Number of subjects: 0
Study 32207705 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex biologically active food supplement Osteomed forte prescribed for 12 months (SG1 and SG2)
Number of subjects: 119
Study 32207705 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex biologically active food supplement Osteomed forte prescribed for 12 months (SG1)
Number of subjects: 119
Study 32207705 — intervention group
Group type: COMPARATOR
Intervention: No intervention (SG3)
Number of subjects: 119
Study 34863038 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021 (100 mg)
Number of subjects: 20
Study 34863038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34054053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DASH diet and low sodium intake
Number of subjects: 343
Study 34054053 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium‐rich DASH diet
Number of subjects: 343
Study 34054053 — intervention group
Group type: COMPARATOR
Intervention: Control diet and high sodium intake
Number of subjects: 343
Study 35871810 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilisation of torus fractures
Number of subjects: 0
Study 35871810 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32135429 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and naloxone treatment
Number of subjects: 0
Study 34747558 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed, humidified CO2 (WHCO2)
Number of subjects: 39
Study 34747558 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 39
Study 32881071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) + Treatment as Usual (TAU) (n = 23)
Number of subjects: 47
Study 32881071 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) (n = 24)
Number of subjects: 47
Study 33431780 — intervention group
Group type: EXPERIMENTAL
Intervention: Support program for dietary behavior change
Number of subjects: 22
Study 33431780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 34501831 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sled-based training
Number of subjects: 0
Study 34501831 — intervention group
Group type: COMPARATOR
Intervention: Traditional unresisted sprint training
Number of subjects: 0
Study 33464758 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK3486
Number of subjects: 80
Study 33464758 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 33464758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32615488 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g lyophilized juçara for 6 weeks
Number of subjects: 35
Study 32615488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no juçara supplementation)
Number of subjects: 35
Study 36469315 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT-based radiomics
Number of subjects: 665
Study 36469315 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model based on selected radiomic features
Number of subjects: 665
Study 33845035 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 Gy intraoperative radiotherapy with electrons (ELIOT) in a single dose to the tumour bed during surgery
Number of subjects: 1305
Study 33845035 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation (WBI) with conventional fractionation (50 Gy given as 25 fractions of 2 Gy, plus a 10 Gy boost)
Number of subjects: 1305
Study 33845035 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in ELIOT group
Number of subjects: 1305
Study 33845035 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in WBI group
Number of subjects: 1305
Study 35147825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers Supporting the Emotional Development of Their Children program (intervention)
Number of subjects: 122
Study 35147825 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 122
Study 33289961 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goals
Number of subjects: 39
Study 33289961 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced use goals
Number of subjects: 39
Study 36308305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet app-based program (n=26)
Number of subjects: 48
Study 36308305 — intervention group
Group type: COMPARATOR
Intervention: Control strengthening exercise program (n=22)
Number of subjects: 48
Study 33676538 — intervention group
Group type: EXPERIMENTAL
Intervention: ActWELL intervention (personalised diet advice and pedometer walking plans)
Number of subjects: 560
Study 33676538 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (usual care)
Number of subjects: 560
Study 33676538 — intervention group
Group type: EXPERIMENTAL
Intervention: ActWELL intervention
Number of subjects: 560
Study 32615994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) for 6 months
Number of subjects: 36
Study 32615994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 36229900 — intervention group
Group type: EXPERIMENTAL
Intervention: LID group (41 patients)
Number of subjects: 75
Study 36229900 — intervention group
Group type: COMPARATOR
Intervention: No-LID group (34 patients)
Number of subjects: 75
Study 32959232 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative blood glucose to lymphocyte ratio with an optimal cutoff value of 3.47 for overall survival.
Number of subjects: 259
Study 32959232 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger male patients with pancreatic body and tail cancer, AJCC 8th N1 stage, without microvascular and peripancreatic fat invasion, CA 19-9 > 200 U/ml.
Number of subjects: 259
Study 32946355 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy (cRT) with a median dose of 30.6 Gy (range, 24-36 Gy)
Number of subjects: 296
Study 32946355 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (NFT)
Number of subjects: 296
Study 32946355 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy (cRT)
Number of subjects: 296
Study 34915329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 28
Study 34915329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 33245972 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cone with BC 150 Series Gutta‐Percha Points and EndoSequence BC Sealer (SC2)
Number of subjects: 50
Study 33245972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave with EndoSequence Gutta‐Percha Points and Ribbon Sealer (CW)
Number of subjects: 50
Study 33245972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral condensation with EndoSequence Gutta‐Percha Points and Ribbon Sealer (CL)
Number of subjects: 50
Study 33245972 — intervention group
Group type: COMPARATOR
Intervention: Single cone with EndoSequence Gutta‐Percha Points and Ribbon Sealer (SC1)
Number of subjects: 50
Study 33245972 — intervention group
Group type: COMPARATOR
Intervention: GuttaCore carrier obturation (GC)
Number of subjects: 50
Study 35134951 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix
Number of subjects: 178
Study 35134951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 34802039 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib combined with risperidone
Number of subjects: 100
Study 34802039 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with risperidone
Number of subjects: 100
Study 34371176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous biliary drainage (PTD)
Number of subjects: 60
Study 34371176 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic stenting (ERCP)
Number of subjects: 60
Study 32452275 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device (WD) with shock paired 12 ms before click
Number of subjects: 95
Study 32452275 — intervention group
Group type: COMPARATOR
Intervention: Wearable device (WD) with clicks and shocks delivered independently
Number of subjects: 95
Study 32452275 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 95
Study 36380284 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (70 or 140 mg/month)
Number of subjects: 777
Study 36380284 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (50-100 mg/day)
Number of subjects: 777
Study 32000261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 362
Study 32000261 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 362
Study 32000261 — intervention group
Group type: COMPARATOR
Intervention: Muscular strength and speed/agility
Number of subjects: 362
Study 35604416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 90
Study 35604416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 33951374 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine (5 µg of recombinant spike protein with 50 µg of Matrix-M1 adjuvant)
Number of subjects: 4387
Study 33951374 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 4387
Study 33951374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4387
Study 32017932 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal plugging in COPD subjects
Number of subjects: 500
Study 32017932 — intervention group
Group type: COMPARATOR
Intervention: Luminal plugging in non-COPD smokers
Number of subjects: 500
Study 32017932 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bronchitis in COPD subjects
Number of subjects: 500
Study 36327545 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional elastic tape
Number of subjects: 27
Study 36327545 — intervention group
Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 27
Study 35142815 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVAC/PCa plus docetaxel and prednisone
Number of subjects: 1182
Study 35142815 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel and prednisone
Number of subjects: 1182
Study 35142815 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVAC/PCa
Number of subjects: 1182
Study 35142815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1182
Study 35276780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate/Low Fat diet (HC)
Number of subjects: 24
Study 35276780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate diet (LC)
Number of subjects: 24
Study 35276780 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 participants)
Number of subjects: 24
Study 33305526 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CONT)
Number of subjects: 35
Study 33305526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 35
Study 33305526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CONT and IER
Number of subjects: 35
Study 35768939 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start (ES)
Number of subjects: 208
Study 33443609 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TT)
Number of subjects: 20
Study 33443609 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TT) combined with resistance training (TT + RT)
Number of subjects: 20
Study 33443609 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TT + RT)
Number of subjects: 20
Study 33043836 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (EX)
Number of subjects: 27
Study 33043836 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 27
Study 33010091 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed brochures focused on rural men affected by cancer
Number of subjects: 114
Study 33010091 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed brochures focused on rural location only
Number of subjects: 114
Study 33010091 — intervention group
Group type: COMPARATOR
Intervention: Generic cancer support material
Number of subjects: 114
Study 33188612 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 240
Study 33328728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nopal cactus fruit juice (NFJ) 3 oz/day
Number of subjects: 40
Study 33328728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35977107 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium meal (CAL; 1000 mg)
Number of subjects: 16
Study 35977107 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric low calcium meal (CON; <10 mg)
Number of subjects: 16
Study 34620664 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI)
Number of subjects: 2037
Study 34620664 — intervention group
Group type: COMPARATOR
Intervention: mycophenolic acid with standard-exposure CNI (MPA+sCNI)
Number of subjects: 2037
Study 36173425 — intervention group
Group type: EXPERIMENTAL
Intervention: Active fronto-motor tACS
Number of subjects: 74
Study 36173425 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 74
Study 36173425 — intervention group
Group type: COMPARATOR
Intervention: Control montage tACS
Number of subjects: 74
Study 36173425 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training
Number of subjects: 74
Study 33454584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg
Number of subjects: 1346
Study 33454584 — intervention group
Group type: COMPARATOR
Intervention: Interferon β‐1a
Number of subjects: 1346
Study 35901768 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) alone
Number of subjects: 0
Study 35901768 — intervention group
Group type: COMPARATOR
Intervention: IV r‐tPA and EVT
Number of subjects: 0
Study 33992274 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta group (A)
Number of subjects: 21
Study 33992274 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy group (B)
Number of subjects: 21
Study 32520773 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35580836 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated dual antiplatelet therapy (DAPT)
Number of subjects: 2816
Study 35580836 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT)
Number of subjects: 2816
Study 33076878 — intervention group
Group type: EXPERIMENTAL
Intervention: Biokesum® (Persicaria minor extract), 250 mg/capsule, twice daily for 6 months
Number of subjects: 36
Study 34551124 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IR HDM tablet (sublingual allergen immunotherapy)
Number of subjects: 0
Study 34280646 — intervention group
Group type: COMPARATOR
Intervention: Conventional strains (CONV; strains B and C: ADG0‐48 > 60 g/d)
Number of subjects: 7216
Study 34280646 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower-growing strains (SL; categorized as FAST, MOD, SLOW)
Number of subjects: 7216
Study 34280646 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain F (FAST category)
Number of subjects: 7216
Study 34280646 — intervention group
Group type: COMPARATOR
Intervention: Conventional strains (CONV) at TW 2
Number of subjects: 7216
Study 34280646 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain F (FAST category) at both TWs
Number of subjects: 7216
Study 34073684 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (PG; n = 15) received a drink containing Lactobacillus casei Shirota (3 × 10^10 CFU)
Number of subjects: 30
Study 34073684 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (CG; n = 15) received a placebo drink
Number of subjects: 30